MedTrace Logo

Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.

NCT01380899 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2021-05-25

Study results available
· View outcomes & findings →

Summary

Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.

At the beginning of PD is difficult for the clinician to distinguish from Parkinsonism Plus Syndromes (PPS) due to the similarity of symptoms and the lack of specific diagnostic tests.

Specific biomarkers to help improve the accuracy of diagnosis and to separate these two entities are highly needed

The histological hallmark for definite diagnosis of PD is the presence of fibrillar aggregates of phosphorylated alpha-synuclein called Lewy bodies (LBs) and Lewy neurites. Previous autopsy-based studies have revealed that alpha-synuclein is deposited in the peripheral autonomic nervous system including the enteric nervous system of the alimentary tract, cardiac plexus, adrenal medulla and skin.

For this reason, in patients with parkinsonism, an alternative tool could be to demonstrate alpha-synuclein fibrillar aggregates in the skin, allowing early and appropriate diagnosis.

Conditions

  • Parkinson Disease
  • Parkinsonian Disorders

Interventions

PROCEDURE

Biopsy of skin

Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.

Sponsors & Collaborators

  • Universidad Autonoma de San Luis Potosí

    lead OTHER

Principal Investigators

  • Ildefonso Rodríguez-Leyva, MD · Hospital Central "Dr. Ignacio Morones Prieto"

  • Maria E Jimenez-Capdeville, PhD · Universidad Autonoma de San Luis Potosi

  • Juan P Castanedo-Cazares, MD · Hospital Dr. Ignacio Morones Prieto

  • Erika G Chi-Ahumada, MC · Facultad de Medicina, UASLP

  • Maria E Jimenez-Capdeville, PhD · Facultad de Medicina

  • Robert A. Norman, MD, PhD. · Independent Dermatologist

Eligibility

Min Age
35 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380899 on ClinicalTrials.gov